\
&
Contact us
\
&
Contact us
Published on | 2 years ago
Programmes Digital, Industry & SpaceThis call is open from Wednesday January 25th to April 25th, 2023.
By participating in the Eureka call, Flanders wants to encourage companies to carry out development projects with partners from the participating regions with a lightweight innovation perspective.
The target group are Flemish companies that wish to develop a joint development project with one or more partners from the participating countries.
The maximum support amount for the Flemish project part is a maximum of € 500,000.
VLAIO only accepts projects related to lightweight innovation.
Important data
Participating countries: Austria, Belgium (Flanders and Wallonia), Canada, France, Luxembourg, South Korea, Spain, Sweden and Switzerland.
All information regarding the call can be found on the website of the EUREKA network at www.eurekanetwork.org/open-calls/network-projects/lightweighting-2023
Registration for the international event is required via www.eurekanetwork.org/open-calls/network-projects/lightweighting-2023
For information regarding the call and the EUREKA modalities, please contact Lieve Apers.
Flemish companies can also receive support from the VLAIO business advisers.
Information on development projects via www.vlaio.be/ontwikkelingsproject.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
